Health
FRUZAQLA(TM) (fruquintinib capsules) now reimbursed in Ontario to treat metastatic colorectal cancer (mCRC)
Takeda Canada Inc. ("Takeda") is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib capsules) in the list of drugs eligible for funding through the Exceptional Access Program (EAP) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for available standard therapies.1 This treatment is eligible for reimbursement if specific clinical criteria are met.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"text","content":"TORONTO, Feb. 2, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib capsules) in the list of drugs eligible for funding through the Exceptional Access Program (EAP) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for available standard therapies.1 This treatment is eligible for reimbursement if specific clinical criteria are met.","length":527,"tagName":"p"},{"type":"image","alt":"Takeda Canada logo (CNW Group/Takeda Canada Inc.)","displaySize":"","headline":null,"caption":"Takeda Canada logo (CNW Group/Takeda Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":210,"url":"https://media.zenfs.com/en/cnwgroup.com/f63b944008a87299ad691f48a47ccc00"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZjohxRdZbKJ2o4ctmoNbBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/f63b944008a87299ad691f48a47ccc00","width":400,"height":210}},"href":"https://mma.prnewswire.com/media/2873921/Takeda_Canada_Inc__FRUZAQLA_TM_%C2%A0_fruquintinib_capsules__now_reim.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""When patients with metastatic colorectal cancer become resistant to all currently funded therapies in their province, many will face a grim future as on average, half of these patients do not survive for more than five months," said Dr. Eric Chen, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. "FRUZAQLA gives those living with mCRC an important new treatment option to potentially give them more time to spend with their family and enjoy other life milestones."","length":525,"tagName":"p"},{"type":"text","content":"mCRC refers to cancer of the colon that has spread to other parts of the body (called distant metastasis), such as to the liver or lungs.2 Colorectal cancer is the third most diagnosed cancer in Ontario with an estimated Approximately 70 per cent of patients with CRC will experience metastatic disease, whether at diagnosis or after treatment with metastases being the main cause of CRC-related death.3,4","length":415,"tagName":"p"},{"type":"text","content":"Ontari...